Aimmune Therapeutics Inc (AIMT)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

8000 MARINA BOULEVARD BRISBANE, CA 94005-1884

Aimmune Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing treatments to protect children with food allergies from accidental exposure. Aimmune Therapeutics serves customers worldwide.

Data based on most recent fiscal year report
Market Cap1.456 Billion Shares Outstanding50.86 Million Avg Volume770.845 Thousand
1-Yr BETA vs S&P TR Current Ratio7.11 Quick Ratio7.11
View SEC Filings from AIMT instead.
Q2 2019 All Institutions Hedge Funds 1
To trade AIMT now:
Filers who had this stock in their top 10: 4 0 (0.0%)
13F Filers holding this stock: 123 15 (1.55%)
Aggregate 13F shares on 06/30/2019: 48.899 Million 8.154 Million
Aggregate 13F shares on 03/31/2019: 47.571 Million 8.762 Million
Percent change: 2.79% -6.94%
Funds creating new positions: 23 3
Funds Adding to an existing position: 48 6
Funds closing out their position: 22 5
Funds reducing their position: 27 4
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AIMT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

1.6 Thousand total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BJERKHOLT ERIC

  • Director
4,282 2019-10-04 1

ENRIGHT PATRICK G

  • Director
0 2019-09-30 2

TAMMENOMS BAKKER JULIET

2,942,500 2019-08-22 0

HAUMANN BRETT K SVP CLIN DEV & CHIEF MED OFC

  • Officer
233,968 2019-08-20 1

IWICKI MARK T

  • Director
0 2019-06-19 1

FALBERG KATHRYN E

  • Director
162,610 2019-06-13 1

BEHAR GREGORY

  • Director
0 2019-06-13 1

DALLAS JAYSON DONALD ALEXANDER

  • Director
4,179 2019-06-13 1

MCDADE MARK

6,000 2019-06-12 1

DILLY STEPHEN GEORGE

  • Director
5,000 2019-06-10 0

SELTZER STACEY DENENBERG

  • Director
10,221 2019-05-23 1

OXTOBY ANDREW CHIEF COMMERCIAL OFFICER

  • Officer
12,000 2019-01-22 2

BARROWCLIFFE SUSAN E. GENERAL MANAGER, EUROPE

  • Officer
9,375 2018-11-19 1

LONGITUDE CAPITAL PARTNERS II, LLC

LONGITUDE VENTURE PARTNERS II, L.P.

TAMMENOMS BAKKER JULIET

ENRIGHT PATRICK G

3,019,734 2018-07-02 0

LONGITUDE CAPITAL PARTNERS II, LLC

TAMMENOMS BAKKER JULIET

LONGITUDE VENTURE PARTNERS II, L.P.

  • 10% Owner
No longer subject to file 2018-06-25 0

SHEEHY DOUGLAS T. SEE REMARKS

  • Officer
33,079 2018-05-22 0

ROZENMAN MARY M. SEE REMARKS

  • Officer
7,004 2018-03-04 0

KNAPP JEFFREY H CHIEF OPERATING OFFICER

  • Officer
12,151 2018-03-04 0

ADELMAN DANIEL C MD CHIEF MEDICAL OFFICER

  • Officer
9,375 2018-03-04 0

FORESITE CAPITAL MANAGEMENT II, LLC

FORESITE CAPITAL FUND II, L.P.

FORESITE CAPITAL MANAGEMENT III, LLC

FORESITE CAPITAL FUND III, L.P.

TANANBAUM JAMES B.

  • 10% Owner
3,643,191 2017-05-26 0

DESOUZA WARREN L. CHIEF FINANCIAL OFFICER

  • Officer
20,681 2017-04-03 0

NESTLE HEALTH SCIENCE US HOLDINGS, INC.

NESTLE SA

NIMCO US, INC.

  • 10% Owner
7,552,084 2016-11-23 0

ELFONT ROBERT MYLES CHIEF MEDICAL OFFICER

  • Officer
299,002 2016-02-26 0

FORESITE CAPITAL MANAGEMENT II, LLC

FORESITE CAPITAL FUND II, L.P.

TANANBAUM JAMES B.

  • 10% Owner
0 2015-08-05 0

RAFF HOWARD V. CHIEF OPERATING OFFICER

  • Officer
428,575 2015-08-05 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

BJERKHOLT ERIC - Officer CHIEF FINANCIAL OFFICER

2019-09-18 P 1,550 $22.57 a 33,574 33,574.00 direct

ENRIGHT PATRICK G - Director

2019-09-17 A 12,500 $22.34 a 45,561 6,058,695.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments